0ME.SG - Twist Bioscience Corp

Stuttgart - Stuttgart Delayed price. Currency in EUR
14.08
+0.03 (+0.21%)
As of 08:10AM CEST. Market open.
Stock chart is not supported by your current browser
Previous close14.05
Open14.08
Bid14.54 x 280000
Ask14.76 x 190000
Day's range14.08 - 14.08
52-week range10.37 - 57.82
Volume0
Avg. volume7
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date03 Aug 2023 - 07 Aug 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Twist Bioscience and CeGaT Launch RNA Fusion Panel to Advance Oncology and Precision Medicine Research

    SOUTH SAN FRANCISCO, Calif., May 31, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and CeGaT GmbH, a global provider of sequencing services for research, clinical studies, and human genetic diagnostics, today announced the launch of the Twist Alliance CeGaT RNA Fusion Panel, which is designed to detect RNA fusions and conduct transcript variant analysis for oncology researc

  • Business Wire

    Twist Bioscience to Present at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., May 24, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming investor conferences:

  • Business Wire

    Twist Bioscience Appoints Robert Werner as Chief Accounting Officer

    SOUTH SAN FRANCISCO, Calif., May 23, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Robert Werner as chief accounting officer.

  • Business Wire

    Twist Bioscience Launches Portfolio of RNA Sequencing Tools

    SOUTH SAN FRANCISCO, Calif., May 22, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of a portfolio of RNA sequencing tools, which includes the Twist RNA Exome, Twist RNA Library Prep Kit and the Twist Ribosomal RNA (rRNA) & Hemoglobin (Globin) Depletion Kit, as well as custom target enrichment capabilities for RNA and whole transcriptome sequencing

  • Business Wire

    Twist Bioscience to Present at ITF World 2023

    SOUTH SAN FRANCISCO, Calif., May 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at Imec Technology Forum (ITF) World 2023 in Antwerp, Belgium on Wednesday, May 17th at 11:10 AM CEST.

  • Simply Wall St.

    Investors Don't See Light At End Of Twist Bioscience Corporation's (NASDAQ:TWST) Tunnel

    With a price-to-sales (or "P/S") ratio of 3.2x Twist Bioscience Corporation ( NASDAQ:TWST ) may be sending very bullish...

  • Zacks

    Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

    Twist Bioscience (TWST) delivered earnings and revenue surprises of 2.75% and 6.31%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results

    SOUTH SAN FRANCISCO, Calif., May 05, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2023 ended March 31, 2023.

  • Zacks

    Horizon Therapeutics (HZNP) Q1 Earnings and Revenues Lag Estimates

    Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of -29.06% and 7.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Motley Fool

    3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers

    If there's one word you could use to describe the kinds of stocks that Cathie Wood buys, it would be "innovative." In fact, three of her ARK Invest exchange-traded funds (ETFs) include the word "innovation" in their names. Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (NASDAQ: BEAM).

  • Zacks

    Twist Bioscience (TWST) Expected to Beat Earnings Estimates: Should You Buy?

    Twist Bioscience (TWST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    Twist Bioscience and Aster Insights Partner on Launch of Next Generation Oncology Panel for Cancer Research

    SOUTH SAN FRANCISCO, Calif. & TAMPA, Fla., April 27, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Aster Insights, a bioinformatics company with the most advanced, direct-patient, lifetime-consented clinicogenomics data to accelerate oncology discovery research, today announced the availability of the AsterExome panel, which can simultaneously enable whole exome sequenc

  • Motley Fool

    Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought

    The iconic money manager with a penchant for aggressive growth is staying active as her exchange-traded funds bounce back in 2023.

  • Business Wire

    Twist Bioscience Enters into Third Collaboration with Astellas to Support Antibody Discovery for Immunotherapies

    SOUTH SAN FRANCISCO, Calif., April 20, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura., "Astellas"), by which Astellas will license a suite of Twist’s VHH antibody libraries to be used by Astellas for drug discovery and development.

  • Business Wire

    Twist Bioscience Launches TCR and CAR Libraries to Enable the Development of Cell Therapies

    SOUTH SAN FRANCISCO, Calif., April 13, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of Twist T-cell Receptor (TCR), and Twist chimeric antigen receptor (CAR) Libraries. These new libraries provide researchers with the ability to rapidly create custom libraries that can enable the identification and development of next generation cell therapies.

  • Business Wire

    Twist Bioscience to Report Fiscal 2023 Second Quarter Financial Results on Friday, May 5, 2023

    SOUTH SAN FRANCISCO, April 13, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, before the opening of the market on Friday, May 5, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discu

  • Business Wire

    DNA Data Storage Alliance Announces Board Appointments

    SAN DIEGO, March 29, 2023--The DNA Data Storage Alliance, a SNIA Technology Affiliate, formed in 2020 by Illumina, Inc. (NASDAQ: ILMN), Microsoft (Nasdaq: MSFT), Twist Bioscience Corporation (NASDAQ: TWST) and Western Digital (NASDAQ: WDC) to create and promote an interoperable storage ecosystem based on DNA as a data storage medium, today announced the appointments of CATALOG Technologies and Quantum Corporation to the governing board of the Alliance. David Turek will represent CATALOG and Don

  • Simply Wall St.

    Shareholders in Twist Bioscience (NASDAQ:TWST) are in the red if they invested a year ago

    Investing in stocks comes with the risk that the share price will fall. And unfortunately for Twist Bioscience...

  • Business Wire

    Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches

    SOUTH SAN FRANCISCO, Calif., March 09, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced an integrated offering of antibody discovery services available to customers. The offering combines Twist Biopharma’s synthetic libraries and AI machine learning with an in vivo immunization approach gained through the acquisition of Abveris, also known as Twist Boston. This

  • Zacks

    Twist Bioscience (TWST) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

    Twist Bioscience (TWST) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

  • Business Wire

    Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery Using New Methodology on Optofluidic Platform

    SOUTH SAN FRANCISCO, Calif., February 14, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today published on the successful discovery of alpaca-derived VHH antibodies using a disruptive, function-forward in vivo discovery workflow developed by Abveris, also known as Twist Boston, on the Beacon optofluidic platform. The paper, titled "Alpaca Single B Cell Interrogation and Hea

  • Zacks

    Twist Bioscience (TWST) Upgraded to Buy: Here's Why

    Twist Bioscience (TWST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Zacks

    Wall Street Analysts Predict a 26.05% Upside in Twist Bioscience (TWST): Here's What You Should Know

    The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Twist Bioscience (TWST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • Business Wire

    Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution at AGBT

    SOUTH SAN FRANCISCO, Calif., February 07, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced technology early access of the Twist enhanced Whole Genome Sequencing (eWGS) solution focused on non-human genomics applications, at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting in Hollywood, Florida. eWGS is a novel solution that enables rese

  • Motley Fool

    Why Twist Bioscience Stock Is Sinking Today

    Shares of Twist Bioscience (NASDAQ: TWST) were sinking 17.5% as of 11:18 a.m. ET on Friday. The steep decline came after the synthetic DNA maker announced its fiscal 2023 first-quarter results. Twist reported Q1 revenue of $54.2 million, up 29% year over year.